BIO

Bio-Rad Laboratories, Inc.Class A

263.26

USD

BIO Earnings Reports

Positive Surprise Ratio

BIO beat 29 of 41 last estimates.

71%

Next Report

Date of Next Report

Apr 29, 2026

Estimate for Q1 26 (Revenue/ EPS)

$593.74M

$1.87

Implied change from Q4 25 (Revenue/ EPS)

-14.35%

-25.20%

Implied change from Q1 25 (Revenue/ EPS)

+1.42%

-26.38%

Bio-Rad Laboratories, Inc.Class A earnings per share and revenue

On Feb 12, 2026, BIO reported earnings of 2.50 USD per share (EPS) for Q4 25, missing the estimate of 2.72 USD, resulting in a -7.97% surprise. Revenue reached 693.20 million, compared to an expected 695.65 million, with a -0.35% difference. The market reacted with a -12.26% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 6 analysts forecast an EPS of 1.87 USD, with revenue projected to reach 593.74 million USD, implying an decrease of -25.20% EPS, and decrease of -14.35% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

BillionToOne, Inc. Class A Common Stock

Report Date

Mar 04, 2026 For Q4 25

Estimate

$0.08

Actual

$0.11

Surprise

+27.02%

Capricor Therapeutics Inc

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.55

Actual

-$0.62

Surprise

-12.56%

Brainsway Ltd. - ADR

Report Date

Mar 11, 2026 For Q4 25

Estimate

$0.13

Actual

$0.14

Surprise

+6.63%

Sundial Growers Inc. Common Shares

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.01

Actual

$0.04

Surprise

+499.62%

Viemed Healthcare, Inc. Common Shares

Report Date

Mar 04, 2026 For Q4 25

Estimate

$0.12

Actual

$0.14

Surprise

+10.85%

Apyx Medical Corporation Common Stock

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$0.05

Actual

-$0.03

Surprise

+48.63%

MacroGenics, Inc.

Report Date

Mar 09, 2026 For Q4 25

Estimate

-$0.29

Actual

-$0.23

Surprise

+22.40%

Biote Corp. Class A Common Stock

Report Date

Mar 11, 2026 For Q4 25

Estimate

$0.05

Actual

$0.06

Surprise

+17.65%

Exagen Inc. Common Stock

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.20

Surprise

-4.22%

Nephros Inc.

Report Date

Mar 12, 2026 For Q4 25

Estimate

$0.01

Actual

$0.01

Surprise

-1.96%

FAQ

What were Bio-Rad Laboratories, Inc.Class A's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Bio-Rad Laboratories, Inc.Class A reported EPS of $2.50, missing estimates by -7.97%, and revenue of $693.20M, -0.35% below expectations.

How did the market react to Bio-Rad Laboratories, Inc.Class A's Q4 2025 earnings?

The stock price moved down -12.26%, changed from $292.42 before the earnings release to $256.56 the day after.

When is Bio-Rad Laboratories, Inc.Class A expected to report next?

The next earning report is scheduled for Apr 29, 2026.

What are the forecasts for Bio-Rad Laboratories, Inc.Class A's next earnings report?

Based on 6 analysts, Bio-Rad Laboratories, Inc.Class A is expected to report EPS of $1.87 and revenue of $593.74M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.